11/25/2025
The FDA granted accelerated approval on Wednesday for a new drug developed by researchers at the Broad Institute that treats non-small cell lung cancer — which had until recently few treatments.
Mark C.Z. Snekvik reports.
The Food and Drug Administration granted accelerated approval on Wednesday for a new drug developed by researchers at the Broad Institute that treats non-small cell lung cancer — the most common type of lung cancer, which had until recently few treatments.